Autolus announces positive primary endpoint data in FELIX trial

pharmafile | December 13, 2022 | News story | Research and Development  

Autolus Therapeutic, a clinical-stage biopharmaceutical company, has announced that the phase 2 FELIX clinical trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukaemia (ALL) has met its primary endpoint of overall remission rate (ORR) at interim levels.


Obe-cel (AUTO1), a CD19 CAR T cell investigational therapy, demonstrated an ORR of 70% in an interim analysis of 50 patients. Obe-cel showed comparable expansion and initial persistence (median follow up 6.4 months) to the data showed in the previous ALLCAR19 study.


Within a wider group of 92 patients, only 3% experienced Grade 3 or higher cytokine release syndrome and 8% experienced Grade 3 or higher immune effector cell-associated neurotoxicity syndrome, highlighting encouraging safety data.


By achieving this milestone, Autolus will receive a $35m payment from Blackstone Life Sciences, with a further $35m as a result of the completion of planned activities supporting the obe-cel manufacturing process.


CEO and chair of Syncona Investment Management Limited, Martin Murphy, said: “The data is consistent with what was previously presented in the ALLCAR19 academic study, underlining the potential of obe-cel as a drug which can provide meaningful impact for patients suffering from ALL, whilst also showing a very positive safety profile in the last line setting.”


Associate attending physician at the Memorial Sloan Kettering Cancer Center, Dr Jae Park, said: “Obe-cel’s high level of anti-leukaemia activity, combined with a well-manageable tolerability profile, is a significant step forward in this underserved disease setting, which is characterised by the explosive growth of the leukaemia and the poor condition of many patients.”


James Spargo

Related Content

No items found

Latest content